Des suppléments de calcium et de vitamine D, ainsi que des exercices, peuvent aider.
OstéoporoseCalciumVitamine D
#3
Les inhibiteurs augmentent-ils le risque de maladies cardiaques ?
Oui, ils peuvent augmenter le risque de maladies cardiaques chez certaines patientes.
Maladies cardiaquesInhibiteurs de l'aromataseRisque
#4
Quels signes indiquent une complication grave ?
Des douleurs thoraciques, des essoufflements ou des saignements doivent être évalués immédiatement.
ComplicationsDouleurs thoraciquesEssoufflement
#5
Comment surveiller les effets à long terme ?
Des examens réguliers et des bilans de santé sont nécessaires pour surveiller les effets à long terme.
SurveillanceEffets à long termeInhibiteurs de l'aromatase
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque du cancer du sein ?
Les facteurs incluent l'âge, les antécédents familiaux et les mutations génétiques.
Facteurs de risqueCancer du seinAntécédents familiaux
#2
Le surpoids est-il un facteur de risque ?
Oui, le surpoids et l'obésité augmentent le risque de cancer du sein.
SurpoidsObésitéCancer du sein
#3
Le tabagisme influence-t-il le risque ?
Oui, le tabagisme est associé à un risque accru de cancer du sein.
TabagismeRisqueCancer du sein
#4
L'âge de la première menstruation a-t-il un impact ?
Oui, une menstruation précoce augmente le risque de cancer du sein.
MenstruationRisqueCancer du sein
#5
Les traitements hormonaux augmentent-ils le risque ?
Oui, les traitements hormonaux substitutifs peuvent augmenter le risque de cancer du sein.
Traitements hormonauxRisqueCancer du sein
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'aromatase : Questions médicales les plus fréquentes",
"headline": "Inhibiteurs de l'aromatase : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inhibiteurs de l'aromatase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-14",
"dateModified": "2026-05-04",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'aromatase"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la synthèse des stéroïdes",
"url": "https://questionsmedicales.fr/mesh/D065088",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la synthèse des stéroïdes",
"code": {
"@type": "MedicalCode",
"code": "D065088",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.399.450.855"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'aromatase",
"alternateName": "Aromatase Inhibitors",
"code": {
"@type": "MedicalCode",
"code": "D047072",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Suresh Thareja",
"url": "https://questionsmedicales.fr/author/Suresh%20Thareja",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda-151 001 (Punjab), India."
}
},
{
"@type": "Person",
"name": "Pooja Ratre",
"url": "https://questionsmedicales.fr/author/Pooja%20Ratre",
"affiliation": {
"@type": "Organization",
"name": "School of Pharmaceutical Sciences, Guru Ghasidas Central University, Bilaspur-495 009 (C.G.), India."
}
},
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Keerti Mishra",
"url": "https://questionsmedicales.fr/author/Keerti%20Mishra",
"affiliation": {
"@type": "Organization",
"name": "School of Pharmaceutical Sciences, Guru Ghasidas Central University, Bilaspur-495 009 (C.G.), India."
}
},
{
"@type": "Person",
"name": "N Lynn Henry",
"url": "https://questionsmedicales.fr/author/N%20Lynn%20Henry",
"affiliation": {
"@type": "Organization",
"name": "Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting.",
"datePublished": "2023-05-31",
"url": "https://questionsmedicales.fr/article/37293258",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2023/3614296"
}
},
{
"@type": "ScholarlyArticle",
"name": "Obesity and Risk of Recurrence in Patients With Breast Cancer Treated With Aromatase Inhibitors.",
"datePublished": "2023-10-02",
"url": "https://questionsmedicales.fr/article/37831449",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1001/jamanetworkopen.2023.37780"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ferrozoles: Ferrocenyl derivatives of letrozole with dual effects as potent aromatase inhibitors and cytostatic agents.",
"datePublished": "2023-07-17",
"url": "https://questionsmedicales.fr/article/37458856",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00775-023-02006-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers.",
"datePublished": "2023-07-07",
"url": "https://questionsmedicales.fr/article/37419892",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41467-023-39613-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "In-silico and in-vitro study reveals ziprasidone as a potential aromatase inhibitor against breast carcinoma.",
"datePublished": "2023-10-02",
"url": "https://questionsmedicales.fr/article/37783782",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-43789-1"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Effets physiologiques des médicaments",
"item": "https://questionsmedicales.fr/mesh/D045505"
},
{
"@type": "ListItem",
"position": 5,
"name": "Hormones, substituts d'hormones et antagonistes d'hormones",
"item": "https://questionsmedicales.fr/mesh/D006730"
},
{
"@type": "ListItem",
"position": 6,
"name": "Antihormones",
"item": "https://questionsmedicales.fr/mesh/D006727"
},
{
"@type": "ListItem",
"position": 7,
"name": "Inhibiteurs de la synthèse des stéroïdes",
"item": "https://questionsmedicales.fr/mesh/D065088"
},
{
"@type": "ListItem",
"position": 8,
"name": "Inhibiteurs de l'aromatase",
"item": "https://questionsmedicales.fr/mesh/D047072"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inhibiteurs de l'aromatase - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inhibiteurs de l'aromatase",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inhibiteurs de l'aromatase",
"description": "Comment diagnostiquer un cancer du sein ?\nQuels tests pour évaluer l'efficacité des inhibiteurs ?\nQuels marqueurs tumoraux sont surveillés ?\nQuand envisager un traitement par inhibiteurs ?\nQuels examens pour détecter des métastases ?",
"url": "https://questionsmedicales.fr/mesh/D047072#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inhibiteurs de l'aromatase",
"description": "Quels sont les effets secondaires des inhibiteurs ?\nComment reconnaître une réaction allergique ?\nQuels symptômes indiquent une progression du cancer ?\nLes inhibiteurs causent-ils des douleurs articulaires ?\nQuels symptômes nécessitent une consultation urgente ?",
"url": "https://questionsmedicales.fr/mesh/D047072#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inhibiteurs de l'aromatase",
"description": "Comment réduire le risque de cancer du sein ?\nLes inhibiteurs sont-ils préventifs pour les femmes à risque ?\nQuel rôle joue la génétique dans le risque ?\nLes dépistages réguliers sont-ils importants ?\nComment l'alimentation influence-t-elle le risque ?",
"url": "https://questionsmedicales.fr/mesh/D047072#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inhibiteurs de l'aromatase",
"description": "Comment fonctionnent les inhibiteurs de l'aromatase ?\nQuels sont les principaux inhibiteurs disponibles ?\nQuelle est la durée du traitement ?\nLes inhibiteurs sont-ils utilisés en prévention ?\nPeut-on combiner les inhibiteurs avec d'autres traitements ?",
"url": "https://questionsmedicales.fr/mesh/D047072#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inhibiteurs de l'aromatase",
"description": "Quelles sont les complications possibles des inhibiteurs ?\nComment gérer l'ostéoporose liée au traitement ?\nLes inhibiteurs augmentent-ils le risque de maladies cardiaques ?\nQuels signes indiquent une complication grave ?\nComment surveiller les effets à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D047072#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inhibiteurs de l'aromatase",
"description": "Quels sont les principaux facteurs de risque du cancer du sein ?\nLe surpoids est-il un facteur de risque ?\nLe tabagisme influence-t-il le risque ?\nL'âge de la première menstruation a-t-il un impact ?\nLes traitements hormonaux augmentent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D047072#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un cancer du sein ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par mammographie, échographie et biopsie."
}
},
{
"@type": "Question",
"name": "Quels tests pour évaluer l'efficacité des inhibiteurs ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des examens d'imagerie sont utilisés pour évaluer la réponse au traitement."
}
},
{
"@type": "Question",
"name": "Quels marqueurs tumoraux sont surveillés ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs comme le CA 15-3 et l'HER2 peuvent être surveillés."
}
},
{
"@type": "Question",
"name": "Quand envisager un traitement par inhibiteurs ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement est envisagé après un diagnostic de cancer du sein hormono-dépendant."
}
},
{
"@type": "Question",
"name": "Quels examens pour détecter des métastases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens comme le scanner et l'IRM sont utilisés pour détecter des métastases."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des inhibiteurs ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets incluent bouffées de chaleur, fatigue, et douleurs articulaires."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une réaction allergique ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent éruption cutanée, démangeaisons, et gonflement."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une progression du cancer ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une douleur accrue, une perte de poids inexpliquée et une fatigue intense peuvent indiquer une progression."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs causent-ils des douleurs articulaires ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs articulaires sont un effet secondaire fréquent des inhibiteurs."
}
},
{
"@type": "Question",
"name": "Quels symptômes nécessitent une consultation urgente ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs thoraciques, des saignements ou des difficultés respiratoires nécessitent une consultation urgente."
}
},
{
"@type": "Question",
"name": "Comment réduire le risque de cancer du sein ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un poids santé, faire de l'exercice et limiter l'alcool peuvent réduire le risque."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs sont-ils préventifs pour les femmes à risque ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être prescrits pour réduire le risque chez les femmes à haut risque."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la génétique dans le risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des mutations génétiques comme BRCA1 et BRCA2 augmentent le risque de cancer du sein."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dépistages réguliers permettent de détecter le cancer à un stade précoce."
}
},
{
"@type": "Question",
"name": "Comment l'alimentation influence-t-elle le risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en fruits, légumes et grains entiers peut réduire le risque."
}
},
{
"@type": "Question",
"name": "Comment fonctionnent les inhibiteurs de l'aromatase ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils bloquent l'aromatase, réduisant la production d'œstrogènes, ce qui freine la croissance tumorale."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux inhibiteurs disponibles ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux incluent l'anastrozole, le létrozole et l'exémestane."
}
},
{
"@type": "Question",
"name": "Quelle est la durée du traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement dure généralement 5 à 10 ans, selon le cas clinique."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs sont-ils utilisés en prévention ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être utilisés en prévention chez les femmes à haut risque de cancer du sein."
}
},
{
"@type": "Question",
"name": "Peut-on combiner les inhibiteurs avec d'autres traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être combinés avec la chimiothérapie ou la radiothérapie selon le cas."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des inhibiteurs ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'ostéoporose, les maladies cardiovasculaires et les fractures."
}
},
{
"@type": "Question",
"name": "Comment gérer l'ostéoporose liée au traitement ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suppléments de calcium et de vitamine D, ainsi que des exercices, peuvent aider."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs augmentent-ils le risque de maladies cardiaques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent augmenter le risque de maladies cardiaques chez certaines patientes."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication grave ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs thoraciques, des essoufflements ou des saignements doivent être évalués immédiatement."
}
},
{
"@type": "Question",
"name": "Comment surveiller les effets à long terme ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers et des bilans de santé sont nécessaires pour surveiller les effets à long terme."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque du cancer du sein ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, les antécédents familiaux et les mutations génétiques."
}
},
{
"@type": "Question",
"name": "Le surpoids est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le surpoids et l'obésité augmentent le risque de cancer du sein."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est associé à un risque accru de cancer du sein."
}
},
{
"@type": "Question",
"name": "L'âge de la première menstruation a-t-il un impact ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une menstruation précoce augmente le risque de cancer du sein."
}
},
{
"@type": "Question",
"name": "Les traitements hormonaux augmentent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements hormonaux substitutifs peuvent augmenter le risque de cancer du sein."
}
}
]
}
]
}
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Institut national de la recherche scientifique (INRS) - Centre Armand-Frappier Santé Biotechnologie, 531, boul. des Prairies, Laval, QC, H7V 1B7, Canada. Electronic address: yossef.lopez@iaf.inrs.ca.
Institut national de la recherche scientifique (INRS) - Centre Armand-Frappier Santé Biotechnologie, 531, boul. des Prairies, Laval, QC, H7V 1B7, Canada; PROTEO, the Québec Network for Research on Protein Function, Engineering, and Applications, 1045 Avenue de la Médecine, Université Laval, Québec, QC, G1V 0A6, Canada. Electronic address: nicolas.doucet@inrs.ca.
Institut national de la recherche scientifique (INRS) - Centre Armand-Frappier Santé Biotechnologie, 531, boul. des Prairies, Laval, QC, H7V 1B7, Canada. Electronic address: thomas.sanderson@iaf.inrs.ca.
Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Third-generation aromatase inhibitors (AIs) are the mainstay of treatment in hormone receptor (HR)-positive breast cancer. Even though it is considered to be a well-tolerated therapy, AI-induced muscu...
This study was performed in accordance with PRISMA guidelines. The literature search and data extraction from all randomized clinical trials (RCTs) were done by two independent investigators. Eligible...
Arthralgia was reported in 13.2 to 68.7% of patients receiving AIs for early-stage breast cancer, while arthralgia induced by CDK4/6 inhibitors occurred in a much lower rate [20.5-41.2%]. Bone pain (5...
CDK4/6 inhibitors might have a protective effect against joint inflammation and arthralgia occurrence. Further studies are warranted to investigate arthralgia incidence in this population....
Clinical studies confirm that obesity is a risk factor for recurrence in postmenopausal women with hormone receptor-positive (HR+) breast cancer. Evidence suggests that women with obesity do not obtai...
To examine the associations of body mass index (BMI) with recurrence....
The cohort study was conducted using data from the Danish Breast Cancer Group and enrolled postmenopausal women diagnosed with stage I to III HR+ breast cancer from 1998 through 2016. Data analysis wa...
BMI was classified as (1) healthy weight (18.5-24.9), (2) overweight (25.0-29.9), (3) obesity (30.0-34.9), and (4) severe obesity (≥35.0) using the World Health Organization guidelines. Healthy weight...
Follow-up began 6 months after breast cancer surgery and continued until the first event of recurrence, contralateral breast cancer, new primary malignant neoplasm, death, emigration, end of clinical ...
A total of 13 230 patients (median [IQR] age at diagnosis, 64.4 [58.6-70.2] years) with information on BMI were enrolled. There were 1587 recurrences with a median (IQR) potential estimated follow-up ...
In this study, obesity was associated with an increased risk of breast cancer recurrence among postmenopausal patients with HR+ early-stage breast cancer treated with aromatase inhibitors. Physicians ...
In the treatment of hormone-dependent cancers, aromatase inhibitors (AI) are receiving increased attention due to some undesirable effects such as the risk of endometrial cancer and thromboembolism of...
Aromatase inhibitors (AIs) reduce recurrences and mortality in postmenopausal patients with oestrogen receptor positive (ER+) breast cancer (BC), but >20% of patients will eventually relapse. Given th...
Aromatase enzyme plays a fundamental role in the development of estrogen receptors, and due to this functionality, the enzyme has gained significant attention as a therapeutic for reproductive disorde...
Monocytes comprise subsets of classical, intermediate and non-classical monocytes with distinct anti- or pro-tumor effects in breast cancer (BC). They are modulated by estrogen, and can contribute to ...
To elucidate whether changes in monocyte subsets are associated with treatment and response, we investigated peripheral blood samples of 73 postmenopausal women with estrogen receptor (ER) positive BC...
When 40 healthy, age-matched women were compared with BC patients before treatment start, ER levels of monocytes did not differ, yet patients presented with a higher frequency of classical and fewer n...
This study identified classical monocytes to be associated with ER positive BC and with patient response to neoadjuvant endocrine treatment and cancer vaccination....
A novel series of 1,2,3-triazole/1,2,4-triazole hybrids 5a, 5b, and 6a-i was designed and synthesized as antiproliferative agents targeting aromatase enzymes. The antiproliferative activity of the new...
This study aimed to evaluate the value of anti-Müllerian hormone (AMH) in predicting ovulation induced by aromatase inhibitors (AI) and pregnancy outcomes in women with polycystic ovary syndrome (PCOS...
From January 2018 to December 2020, this prospective cohort study enrolled women with PCOS aged between 18 and 45 years who underwent ovulation induction using AI protocol and intrauterine inseminatio...
In total, 64% of 65 women with PCOS were recruited following AI treatment, and the clinical pregnancy rate was 19.4% following IUI. Patients who experienced ovulation had a lower mean serum AMH concen...
In women with PCOS, the AMH level does not predict ovarian responsiveness to AI treatment, but it does predict the success of IUI cycles....
Breast cancer (BC) is a leading cause of premature death in women and the most expensive malignancy to treat. Since the introduction of targeted therapies has resulted in changes to BC therapy practic...
To systematically review and examine the quality of the available economic studies of AIs in estrogen receptor-positive breast cancer....
A literature search was performed using six relevant databases (MEDLINE, Embase, Database of Abstracts of Reviews of Effects, Health Technology Assessment Database, NHS Economic Evaluation Database, a...
A total of eight studies were included in the review; six (75%) were performed from the healthcare providers' perspective. They were conducted in seven different countries, and all were model-based an...
AIs are generally considered cost-effective compared to tamoxifen in estrogen receptor-positive breast cancer. The overall quality of the included studies was between high and average but characterizi...
Aromatase inhibitors are used post-surgical intervention in postmenopausal patients with breast cancer. However, these drugs accelerate decline in bone mineral density (BMD), which is countered by use...
This was a single-center retrospective study. Postoperative hormone receptor-positive breast cancer patients with low T-scores biannually received denosumab from the time of initiation of aromatase in...
The median patient age of the 55 patients included in this study was 69 (range: 51-90) years. BMD gradually increased in the lumbar spine and femoral neck and u-NTX levels were lowest at 3 months post...
Denosumab increased BMD in patients treated with aromatase inhibitors. The u-NTX level decreased soon after start of denosumab treatment, and its change ratio is predictive of improvement in BMD....
